Abstract
Statins can lower LDL cholesterol concentration by an average of 1.8 mmol/l which reduces the risk of IHD events by about 60% and stroke by 17%.
Keywords
MeSH Terms
Affiliated Institutions
Related Publications
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial)
The primary objective of this 6-week, parallel-group, open-label, randomized, multicenter trial was to compare rosuvastatin with atorvastatin, pravastatin, and simvastatin acros...
Meta‐analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes
Aims Since 2002, there have been five major outcome trials of statins reporting findings from more than 47 000 subjects. As individual trial results differed, we performed a met...
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial
Individuals with diabetes are at increased risk of cardiovascular morbidity and mortality, although typically their plasma concentrations of LDL cholesterol are similar to those...
Comparison of Once-Daily, niacin Extended-Release/lovastatin with standard doses of atorvastatin and simvastatin (the advicor versus other Cholesterol-Modulating agents trial evaluation [ADVOCATE])
This study compared the relative efficacy of a once-daily niacin extended-release (ER)/lovastatin fixed-dose combination with standard doses of atorvastatin or simvastatin, with...
Publication Info
- Year
- 2003
- Type
- review
- Volume
- 326
- Issue
- 7404
- Pages
- 1423-0
- Citations
- 1717
- Access
- Closed
External Links
Social Impact
Social media, news, blog, policy document mentions
Citation Metrics
Cite This
Identifiers
- DOI
- 10.1136/bmj.326.7404.1423
- PMID
- 12829554
- PMCID
- PMC162260